Diagnosing the decline in pharmaceutical R&D efficiency
The DOI matches its Crossref record; 85 of the 85 references it cites were found in a registry or an index.
Abstract
The past 60 years have seen huge advances in many of the scientific, technological and managerial factors that should tend to raise the efficiency of commercial drug research and development (RD). Yet the number of new drugs approved per billion US dollars spent on RD has halved roughly every 9 years since 1950, falling around 80-fold in inflation-adjusted terms. There have been many proposed solutions to the problem of declining RD efficiency. However, their apparent lack of impact so far and the contrast between improving inputs and declining output in terms of the number of new drugs make it sensible to ask whether the underlying problems have been correctly diagnosed. Here, we discuss four factors that we consider to be primary causes, which we call the 'better than the Beatles' problem; the 'cautious regulator' problem; the 'throw money at it' tendency; and the 'basic research-brute force' bias. Our aim is to provoke a more systematic analysis of the causes of the decline in RD efficiency.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“For over fifty years, the pharmaceutical industry has seen the cost of developing drugs increase exponentially from tens of millions in the 1950s to billions of dollars today, even when the data is adjusted for inflation [1].”
From Drug design on quantum computers (2024) · doi:10.1038/s41567-024-02411-5 · cites this paper as [1]
Citations
Cites
Collective dynamics of ‘small-world’ networks
Watts, D. J., & Strogatz, S. H. (1998) · Nature · doi:10.1038/30918 · Cited by 43,060
Lipinski, C. A., Lombardo, F., Dominy, B. W., & Feeney, P. J. (2001) · Advanced Drug Delivery Reviews · doi:10.1016/s0169-409x(00)00129-0 · Cited by 18,139
OLSSON, A. G., McMurray, J. J. V., Thorgeirsson, G., Spaulding, C. M., Slattery, J., Pyörälà, K., Færgeman, O., Wright, R. S., Berg, K. M., Wilhelmsen, L., et al. (1994) · The Lancet · Cited by 8,467
Improved survival with vemurafenib in melanoma with BRAF V600E mutation
Chapman, P. B., Hauschild, A., Robert, C., Haanen, J. B., Ascierto, P., Larkin, J., Dummer, R., Garbe, C., Testori, A., Maio, M., et al. (2011) · New England Journal of Medicine · doi:10.1056/nejmoa1103782 · Cited by 7,720
Identification of the transforming EML4–ALK fusion gene in non-small-cell lung cancer
Soda, M., Choi, Y. L., Enomoto, M., Takada, S., Yamashita, Y., Ishikawa, S., Fujiwara, S.-I., Watanabe, H., Kurashina, K., Hatanaka, H., et al. (2007) · Nature · doi:10.1038/nature05945 · Cited by 5,439 · cited 1×
“It is hard to look at the genesis of drugs like crizotini”
BackgroundCan the pharmaceutical industry reduce attrition rates?
Kola, I., & Landis, J. (2004) · Nature Reviews Drug Discovery · doi:10.1038/nrd1470 · Cited by 4,167
SCANDINAVIANSIMVASTATINSURVIVAL (1994) · The Lancet · doi:10.1016/s0140-6736(94)90566-5 · Cited by 3,645
How to improve R&D productivity: the pharmaceutical industry's grand challenge
Paul, S. M., Mytelka, D. S., Dunwiddie, C. T., Persinger, C. C., Munos, B. H., Lindborg, S. R., & Schacht, A. L. (2010) · Nature Reviews Drug Discovery · doi:10.1038/nrd3078 · Cited by 3,566
How many drug targets are there?
Overington, J. P., Al-Lazikani, B., & Hopkins, A. L. (2006) · Nature Reviews Drug Discovery · doi:10.1038/nrd2199 · Cited by 3,505
Hopkins, A. L., & Groom, C. R. (2002) · Nature Reviews Drug Discovery · doi:10.1038/nrd892 · Cited by 3,305 · cited 1×
“First, estimates of the number of potential drug target”
Background
Research works printed but not linked: 6
- Ruffolo, R. R. Engineering success: Wyeth redefines its research & development organisation. Drug Discovery World website [online] , (2005).
- Young, M. P. Prediction v Attrition. Drug Discovery World website [online] , (2008).
- Healy, D. The Psychopharmacologists: Volume 2 93–118 (Hodder Arnold, London, 1999).
- Healy, D. The Psychopharmacologists: Volume 2 259–264 (Hodder Arnold, London, 1999).
- Mathieu, M. P. (ed.) Parexel's Bio/Pharmaceutical R&D Statistical Sourcebook 2010/2011 163–261 (Barnett International, Needham, Massachusetts, 2010).
- Munos, B. How to avert biopharma's R&D crisis. In Vivo 29, 2011800050 (2011).
Cited by
Items 401–500 of 1,002
Kimber, T. B., Gagnebin, M., & Volkamer, A. (2021) · Artificial Intelligence in the Life Sciences · doi:10.1016/j.ailsci.2021.100014 · Cited by 73
Open innovation and the effects of Crowdsourcing in a pharma ecosystem
Christensen, I., & Karlsson, C. (2018) · Journal of Innovation & Knowledge · doi:10.1016/j.jik.2018.03.008 · Cited by 46
A Scaffold‐Diversity Synthesis of Biologically Intriguing Cyclic Sulfonamides
Zimmermann, S., Akbarzadeh, M., Otte, F., Carsten Strohmann, B., Sankar, M. G., Ziegler, S., Pahl, A., Sievers, S., & Kumar, K. (2019) · Chemistry - A European Journal · doi:10.1002/chem.201904175 · Cited by 47
Drug Repositioning for Alzheimer’s Disease: Finding Hidden Clues in Old Drugs
Ihara, M., & Saito, S. (2020) · Journal of Alzheimer’s Disease · doi:10.3233/jad-200049 · Cited by 44
An analysis of original research contributions toward FDA-approved drugs
Patridge, E. V., Gareiss, P. C., Kinch, M. S., & Hoyer, D. (2015) · Drug Discovery Today · doi:10.1016/j.drudis.2015.06.006 · Cited by 45
RxRx1: A Dataset for Evaluating Experimental Batch Correction Methods
Sypetkowski, M., Rezanejad, M., Saberian, S., Kraus, O. Z., Urbanik, J., Taylor, J., Mabey, B., Victors, M. L., Yosinski, J., Sereshkeh, A. R., et al. (2023) · IEEE/CVF Conference on Computer Vision and Pattern Recognition Workshops (CVPRW) · doi:10.1109/cvprw59228.2023.00451 · Cited by 75
“Such screens are capable of generating large amounts of data that, when coupled with modern machine learning methods, could help answer fundamental questions in biology and solve the problem of rising costs in drug discovery, which are now estimated to be well over 2 billion per approved drug [16, 44].”
BackgroundMaximising success in multidrug formulation development: A review
Kavanagh, O. N., Albadarin, A. B., Croker, D. M., Healy, A. M., & Walker, G. (2018) · Journal of Controlled Release · doi:10.1016/j.jconrel.2018.05.024 · Cited by 45
Radiopharmaceutical enhancement by drug delivery systems: A review
Kleynhans, J., Grobler, A., Ebenhan, T., Sathekge, M. M., & Zeevart, J. (2018) · Journal of Controlled Release · doi:10.1016/j.jconrel.2018.08.008 · Cited by 45
The application of positron emission tomography (PET) imaging in CNS drug development
Suridjan, I., Comley, R. A., & Rabiner, E. A. (2018) · Brain Imaging and Behavior · doi:10.1007/s11682-018-9967-0 · Cited by 45
Preventive healthcare policies in the US: solutions for disease management using Big Data Analytics
Batarseh, F. A., Ghassib, I. H., Chong, D., & Su, P.-H. (2020) · Journal Of Big Data · doi:10.1186/s40537-020-00315-8 · Cited by 53
Pharmaceutical regulation in Europe and its impact on corporate R&D
Eger, S., & Mahlich, J. (2014) · Health Economics Review · doi:10.1186/s13561-014-0023-5 · Cited by 57
“The trend of falling R&D productivity in the pharmaceutical industry has been termed ‘Eroom’s Law’ [83] in contrast to ‘Moore’s law’ that describes the productivity jumps in the semiconductor industry (in fact it is ‘Moore’s Law’ backwards).”
BackgroundCui, J. J., Shen, H., Tran‐Dubé, M., Nambu, M. D., McTigue, M. A., Grodsky, N. B., Ryan, K., Yamazaki, S., Aguirre, S. A., Parker, M., et al. (2013) · Journal of Medicinal Chemistry · doi:10.1021/jm400926x · Cited by 45
Eshon, J., Nicastri, K. A., Schmid, S. C., Raskopf, W. T., Guzei, I. A., Fernández, I., & Schomaker, J. M. (2020) · Nature Communications · doi:10.1038/s41467-020-15134-x · Cited by 43
Bueters, T., Ploeger, B. A., & Visser, S. A. G. (2013) · Drug Discovery Today · doi:10.1016/j.drudis.2013.05.001 · Cited by 43
Flow chemistry approaches directed at improving chemical synthesis
Baxendale, I. R., Brocken, L., & Mallia, C. J. (2013) · Green Processing and Synthesis · doi:10.1515/gps-2013-0029 · Cited by 43
Systems biology, complexity, and the impact on antiepileptic drug discovery
Margineanu, D. G. (2013) · Epilepsy & Behavior · doi:10.1016/j.yebeh.2013.08.029 · Cited by 45
“A widely recognized multiyear decline in the productivity of the pharmaceutical industry (Pharma), while the investment in R&D uninterruptedly increased [23–25] and the scientific and technological conditions progressed, incites searching the causes of this worrying reality [26].”
BackgroundThe future of machine learning for small-molecule drug discovery will be driven by data
Durant, G., Boyles, F., Birchall, K., & Deane, C. M. (2024) · Nature Computational Science · doi:10.1038/s43588-024-00699-0 · Cited by 48
“From 1950 to 2012, there has been a halving of approved drugs per US$1 billion spent on research and development every 9 years, a trend coined as ‘Eroom’s law’ 5 .”
Bakken, G. A., Bell, A., Boehm, M., Everett, J. R., Gonzales, R., Hepworth, D., Klug-McLeod, J. L., Lanfear, J., Loesel, J., Mathias, J. P., et al. (2012) · Journal of Chemical Information and Modeling · doi:10.1021/ci300372a · Cited by 42
Buying big into biotech: scale, financing, and the industrial dynamics of UK biotech, 1980-2009
Hopkins, M. M., Crane, P. A., Nightingale, P., & Baden‐Fuller, C. W. F. (2013) · Industrial and Corporate Change · doi:10.1093/icc/dtt022 · Cited by 42
“encouraging reductionist, scalable research at the expense of lower throughput, more tacit-knowledge–based approaches (Scannell et al., 2012).”
BackgroundLeveridge, M. V., Buxton, R., Argyrou, A., Francis, P. L., Leavens, B. J., West, A., Rees, M., Hardwicke, P., Bridges, A. M., Ratcliffe, S. J., et al. (2013) · SLAS DISCOVERY · doi:10.1177/1087057113496276 · Cited by 42
“Despite this ongoing debate, there is also widespread agreement that the focus of much R&D effort is now on hard-to-treat, rare diseases, often exploring new areas of biology and novel target classes that may offer greater commercial and therapeutic value in terms of differentiation in the marketplace.(3,5) For these…”
BackgroundProduction of Drug-Loaded Polymeric Nanoparticles by Electrospraying Technology
Sosnik, A. (2014) · Journal of Biomedical Nanotechnology · doi:10.1166/jbn.2014.1887 · Cited by 47
Nerattini, F., Chelli, R., & Procacci, P. (2016) · Physical Chemistry Chemical Physics · doi:10.1039/c5cp05521k · Cited by 47
Overcoming the Declining Trends in Innovation and Investment in Cardiovascular Therapeutics
Norman, G. A. V. (2017) · JACC Basic to Translational Science · doi:10.1016/j.jacbts.2017.09.002 · Cited by 50
“The number of new CVD drugs starting trials of all stages between 1990 and 2012 declined in both absolute and relative numbers (Figure 1) (2,13).”
BackgroundInfluentialMicrofluidic system for modelling 3D tumour invasion into surrounding stroma and drug screening
Du, Z., Mi, S., Yi, X., Xu, Y., & Sun, W. (2018) · Biofabrication · doi:10.1088/1758-5090/aac70c · Cited by 42
Zabiulla, Z., Al-Ostoot, F. H., Asha, M. S., Al‐Ghorbani, M., & Khanum, S. A. (2021) · Journal of the Iranian Chemical Society · doi:10.1007/s13738-021-02293-x · Cited by 42
Safizadeh, H., Simpkins, S. W., Nelson, J., Li, S. C., Piotrowski, J. S., Yoshimura, M., Yashiroda, Y., Hirano, H., Osada, H., Yoshida, M., et al. (2021) · Journal of Chemical Information and Modeling · doi:10.1021/acs.jcim.0c00993 · Cited by 44
Predicting Drug Approvals: The Novartis Data Science and Artificial Intelligence Challenge
Siah, K. W., Kelley, N. W., Ballerstedt, S., Holzhauer, B., Lyu, T., Mettler, D., Sun, S. B., Wandel, S., Yang, Z. H., Zhou, B., et al. (2021) · Patterns · doi:10.1016/j.patter.2021.100312 · Cited by 49
Patient-Specific Stem Cells and Cardiovascular Drug Discovery
Mordwinkin, N. M., Lee, A. S., & Wu, J. C. (2013) · JAMA · doi:10.1001/jama.2013.282409 · Cited by 41
Hwang, T. J. (2013) · PLoS ONE · doi:10.1371/journal.pone.0071966 · Cited by 51
“’ [1], [2] There is some evidence to suggest that development risks, which refer to the likelihood that the R&D process will be terminated due to safety, efficacy, or commercial concerns, remain high.”
BackgroundCai, Y., Cao, X., & Aballay, A. (2014) · mBio · doi:10.1128/mbio.01235-14 · Cited by 42
“This is highlighted by the fact that even though there has been a more than 10-fold increase in drug development spending during the last few years, there has been no growth in new drug approvals (1).”
BackgroundA comparative effectiveness study of eSource used for data capture for a clinical research registry
Nordo, A. H., Eisenstein, E. L., Hawley, J., Vadakkeveedu, S., Pressley, M., Pennock, J., & Sanderson, I. (2017) · International Journal of Medical Informatics · doi:10.1016/j.ijmedinf.2017.04.015 · Cited by 38
“For more than 60 years, the cost of conducting biomedical research has increased exponentially while net productivity has declined [1,2].”
BackgroundCOVER: conformational oversampling as data augmentation for molecules
Hemmerich, J., Asilar, E., & Ecker, G. F. (2020) · Journal of Cheminformatics · doi:10.1186/s13321-020-00420-z · Cited by 42
“Additionally, over the last years pharmaceutical industries have faced a decline in newly marketed drugs [4, 5].”
BackgroundAlsultan, A., Alghamdi, W. A., Alghamdi, J., Alharbi, A., Aljutayli, A., Albassam, A. A., Almazroo, O. A., & Alqahtani, S. (2020) · Saudi Pharmaceutical Journal · doi:10.1016/j.jsps.2020.08.012 · Cited by 46
“The probability of clinical development success is approximately 10% with few drugs surviving beyond clinical trials (Scannell et al., 2012).”
BackgroundIn Vitro Cancer Models: A Closer Look at Limitations on Translation
Antunes, N., Kundu, B., Kundu, S. C., Reis, R. L., & Correlo, V. M. (2022) · Bioengineering · doi:10.3390/bioengineering9040166 · Cited by 45
Livingston, C. A., Fabre, K. M., & Tagle, D. A. (2016) · Computational and Structural Biotechnology Journal · doi:10.1016/j.csbj.2016.04.003 · Cited by 42
Human ex-vivo action potential model for pro-arrhythmia risk assessment
Page, G., Ratchada, P., Miron, Y., Steiner, G., Ghetti, A., Miller, P. E., Reynolds, J. A., Wang, K., Greiter‐Wilke, A., Polonchuk, L., et al. (2016) · Journal of Pharmacological and Toxicological Methods · doi:10.1016/j.vascn.2016.05.016 · Cited by 43
Integrated deep learned transcriptomic and structure-based predictor of clinical trials outcomesPreprint
Artemov, A. V., Lane, E., Vanhaelen, Q., Aliper, A. M., Ozerov, I. V., & Zhavoronkov, A. A. (2016) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/095653 · Cited by 47
“Throughout the last decade many studies have revealed a continuous increase in the total cost of developing successful pharmaceutical products (Munos and Chin 2011; Mignani et al. 2016; Scannell et al. 2012).”
BackgroundYuan, Y., Yu, L.-L., Bi, C., Huang, L., Su, B., Nie, J., Dou, Z., Yang, S., & Li, Y. (2025) · Chinese Medicine · doi:10.1186/s13020-025-01075-4 · Cited by 46
“A variety of complex molecular networks participate in the mechanism of many common diseases, especially when dealing with complex diseases, single target drugs are difficult to achieve the expected efficacy [12].”
Ehmann, F., Amati, M. P., Salmonson, T., Posch, M., Vamvakas, S., Hemmings, R., Eichler, H., & Schneider, C. K. (2013) · Clinical Pharmacology & Therapeutics · doi:10.1038/clpt.2013.14 · Cited by 40
Neue Modalitäten für schwierige Zielstrukturen in der Wirkstoffentwicklung
Valeur, E., Guéret, S. M., Adihou, H., Gopalakrishnan, R., Lemurell, M., Waldmann, H., Grossmann, T. N., & Plowright, A. T. (2017) · Angewandte Chemie · doi:10.1002/ange.201611914 · Cited by 40
Taking advantage of emergence for complex innovation eco-systems
Dougherty, D. J. (2017) · Journal of Open Innovation Technology Market and Complexity · doi:10.1186/s40852-017-0067-y · Cited by 40
“Scannell et al. (2012) point out that most of the R&D costs are in failures, so they recommend that firms develop a chief dead drug officer to investigate the failures.”
BackgroundInfluentialRepurposing Fenamic Acid Drugs To Combat Multidrug-Resistant Neisseria gonorrhoeae
Seong, Y. J., Alhashimi, M., Mayhoub, A. S., Mohammad, H. T., & Seleem, M. N. (2020) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.02206-19 · Cited by 43
“discovery but also is generally more likely to succeed, as the drug’s toxicity and pharmacological properties are better characterized than those of newly synthesized compounds (12, 13).”
BackgroundAssessment of the Antitumor Potential of Umbelliprenin, a Naturally Occurring Sesquiterpene Coumarin
Shahzadi, I., Ali, Z., Baek, S. H., Mirza, B., & Ahn, K. S. (2020) · Biomedicines · doi:10.3390/biomedicines8050126 · Cited by 41
Ayensa-Jiménez, J., Pérez-Aliacar, M., Ranđelović, T., Oliván, S., Fernández, L. J., Sanz‐Herrera, J. A., Ochoa, I., Doweidar, M. H., & Doblaré, M. (2020) · Scientific Reports · doi:10.1038/s41598-020-78215-3 · Cited by 47
Armstrong, A., Horry, K., Cui, T., Hulley, M. E., Turner, R. C., Farid, S. S., Goldrick, S., & Bracewell, D. G. (2021) · Journal of Chromatography A · doi:10.1016/j.chroma.2021.461914 · Cited by 40
De Lellis, L., Veschi, S., Tinari, N., Mokini, Z., Carradori, S., Brocco, D., Florio, R., Grassadonia, A., & Cama, A. (2021) · Cancers · doi:10.3390/cancers13163946 · Cited by 40
Monitoring of Drug Release via Intra Body Communication with an Edible Pill
Lamanna, L., Cataldi, P., Friuli, M., Demitri, C., & Caironi, M. (2022) · Advanced Materials Technologies · doi:10.1002/admt.202200731 · Cited by 40
Koutroumpa, N.-M., Papavasileiou, K. D., Papadiamantis, A. G., Melagraki, G., & Afantitis, A. (2023) · International Journal of Molecular Sciences · doi:10.3390/ijms24076573 · Cited by 47
Norris, J. L., Farrow, M. A., Gutierrez, D. B., Palmer, L. D., Muszynski, N. D., Sherrod, S. D., Pino, J. C., Allen, J. L., Spraggins, J. M., Lubbock, A. L. R., et al. (2017) · Journal of Proteome Research · doi:10.1021/acs.jproteome.6b01004 · Cited by 46
Poonam, P., Gupta, Y. A., Gupta, N., Singh, S., Wu, L., Chhikara, B. S., Rawat, M., & Rathi, B. (2018) · Medicinal Research Reviews · doi:10.1002/med.21486 · Cited by 40
Drug repositioning for cancer in the era of AI, big omics, and real-world data
Wieder, R., & Adam, N. R. (2022) · Critical Reviews in Oncology/Hematology · doi:10.1016/j.critrevonc.2022.103730 · Cited by 42
The changing landscape of medicinal chemistry optimization
Rácz, A., Mihalovits, L. M., Beckers, M., Fechner, N., Stiefl, N., Sirockin, F., McCoull, W., Evertsson, E., Lemurell, M., Makara, G. M., et al. (2025) · Nature Reviews Drug Discovery · doi:10.1038/s41573-025-01225-1 · Cited by 52
Mullane, K., & Williams, M. J. (2015) · Biochemical Pharmacology · doi:10.1016/j.bcp.2015.07.002 · Cited by 42
“In addressing the decade plus productivity crisis in pharma that is, putting aside the debatable semantics of the actual number of drug approvals per year, a reflection of the disconnect between research investments and approved drugs [40], various solutions that have been proposed.”
BackgroundParks, L. G., Beyer, B. K., Breslin, W., Brown, T. R., Chapin, R. E., Campion, S., Enright, B., Faustman, E., Foster, P. M. D., Hartung, T., et al. (2013) · ALTEX · doi:10.14573/altex.2013.3.353 · Cited by 43
“Similarly, the pharmaceutical industry has struggled to identify and implement effective early safety screening approaches to offset the rising cost of pharmaceutical development (Scannell et al., 2012; McKim, 2010).”
BackgroundDing, Z., Ge, J.-P., Wu, X.-M., & Zheng, X.-N. (2013) · Scientometrics · doi:10.1007/s11192-013-0968-x · Cited by 39
“Worse still, the increased R&D pharmaceutical investment has not witnessed parallel increase in the production of new drugs (Scannell et al. 2012).”
BackgroundApproval probabilities and regulatory review patterns for anticancer drugs in the European Union
Hartmann, M., Mayer‐Nicolai, C., & Pfaff, O. (2013) · Critical Reviews in Oncology/Hematology · doi:10.1016/j.critrevonc.2013.01.004 · Cited by 39
Crowdsourced ‘R&D’ and medical research: Table 1
Callaghan, C. W. (2015) · British Medical Bulletin · doi:10.1093/bmb/ldv035 · Cited by 39
“28 Given the shift to a ‘ large molecule ’ protein-based era of medical research (which has supplanted the ‘ small molecule ’ chemistry era) 30 and its increasing complexity, these applications of crowdsourced R&D offer a useful complement to other medical research methodologies.”
BackgroundBurt, T., Button, K. S., Thom, H. H. Z., Noveck, R. J., & Munafo, M. R. (2017) · Clinical and Translational Science · doi:10.1111/cts.12478 · Cited by 46
Ayoubi, S., Sheikh, S. P., & Eskildsen, T. V. (2017) · Cardiovascular Research · doi:10.1093/cvr/cvx125 · Cited by 42
“Similarly, many drugs that have proved to be effective in mice have been ineffective in human clinical trials.(93) Transgenic animal models have helped to avoid species to species differences but the generation and breeding is costly and slow.”
Andriani, P., & Kamińska, R. (2020) · Research Policy · doi:10.1016/j.respol.2020.104171 · Cited by 41
Florio, R., Carradori, S., Veschi, S., Brocco, D., Genni, T. D., Cirilli, R., Casulli, A., Cama, A., & Lellis, L. D. (2021) · Pharmaceuticals · doi:10.3390/ph14040372 · Cited by 43
“fail throughout the clinical trial phases needed before drug approval [2,3].”
BackgroundThe fall and rise of pharmacology – (Re-)defining the discipline?
Winquist, R. J., Mullane, K., & Williams, M. J. (2013) · Biochemical Pharmacology · doi:10.1016/j.bcp.2013.09.011 · Cited by 44
“archival with minimal utility in understanding basic cell function and the search for novel therapeutics [27–29].”
BackgroundThe evolution of drug discovery: from phenotypes to targets, and back
Al‐Ali, H. (2016) · MedChemComm · doi:10.1039/c6md00129g · Cited by 46
Fanizza, F., Boeri, L., Donnaloja, F., Perottoni, S., Forloni, G., Giordano, C., & Albani, D. (2023) · ACS Biomaterials Science & Engineering · doi:10.1021/acsbiomaterials.3c00346 · Cited by 38
Yang, W., Li, T., Liao, S., Zhou, J., & Huang, L. (2024) · TrAC Trends in Analytical Chemistry · doi:10.1016/j.trac.2024.117569 · Cited by 44
Troubleshooting and deconvoluting label-free cell phenotypic assays in drug discovery
Ye, F. (2013) · Journal of Pharmacological and Toxicological Methods · doi:10.1016/j.vascn.2013.01.004 · Cited by 38
“(Scannell, 2012), the potential of most drugs to have polypharmacology and the complexity of disease networks, there are renewed interests in”
BackgroundKnowledge-based Fragment Binding Prediction
Tang, G. W., & Altman, R. B. (2014) · PLoS Computational Biology · doi:10.1371/journal.pcbi.1003589 · Cited by 37
“In recent years, the productivity of pharmaceutical research and development has declined [1,2].”
BackgroundOpen Access Could Transform Drug Discovery: A Case Study of JQ1
Arshad, Z., Smith, J. A., Roberts, M., Lee, W. H., Davies, B. M., Bure, K., Holländer, G. A., Dopson, S., Bountra, C., & Brindley, D. A. (2016) · Expert Opinion on Drug Discovery · doi:10.1517/17460441.2016.1144587 · Cited by 48
Principles of dynamical modularity in biological regulatory networks
Deritei, D., Aird, W. C., Ercsey-Ravasz, M., & Regan, E. R. (2016) · Scientific Reports · doi:10.1038/srep21957 · Cited by 42
“(1) a method to cut the network into individual switches by automatically generating reduced Boolean rules that dictate the internal dynamics of an arbitrary subgraph (detailed in Supplementary Methods 4.”
MethodGomes, A. C., & Sárria, M. P. (2018) · InTech eBooks · doi:10.5772/65837 · Cited by 39
Karatzas, E., Zamora, J. E., Athanasiadis, E. I., Dellis, D., Cournia, Z., & Spyrou, G. M. (2020) · Bioinformatics · doi:10.1093/bioinformatics/btz976 · Cited by 39
Kalaria, D. R., Parker, K., Reynolds, G., & Laru, J. (2020) · Drug Discovery Today · doi:10.1016/j.drudis.2019.12.012 · Cited by 41
Hunsberger, J. G., Efthymiou, A. G., Malik, N., Behl, M., Mead, I., Zeng, X., Simeonov, A. M., & Rao, M. S. (2015) · Stem Cells and Development · doi:10.1089/scd.2014.0531 · Cited by 40
Thenuwara, G., Javed, B., Singh, B., & Tian, F. (2024) · Sensors · doi:10.3390/s24092865 · Cited by 42
Mudduluru, G., Walther, W., Kobelt, D., Dahlmann, M., Treese, C., Assaraf, Y. G., & Stein, U. (2016) · Drug Resistance Updates · doi:10.1016/j.drup.2016.03.002 · Cited by 39
Schuler, J., Hudson, M. L., Schwartz, D. G., & Samudrala, R. (2017) · Molecules · doi:10.3390/molecules22101777 · Cited by 39
“[132] argue that targeting a single molecule with a compound is a bias in and of itself.”
BackgroundRecent advances in an organ-on-a-chip: biomarker analysis and applications
Li, X., & Tian, T. (2018) · Analytical Methods · doi:10.1039/c8ay00970h · Cited by 38
Leveraging Big Data to Transform Drug Discovery
Glicksberg, B. S., Li, L., Chen, R., Dudley, J. T., & Chen, B. (2019) · Methods in molecular biology · doi:10.1007/978-1-4939-9089-4_6 · Cited by 37
CEO research orientation, organizational context, and innovation in the pharmaceutical industry
van de Wal, N., Boone, C., Gilsing, V. A., & Walrave, B. (2019) · R and D Management · doi:10.1111/radm.12394 · Cited by 43
“Indeed, the pharmaceutical industry has experienced a decline in innovation outcomes (Scannell et al., 2012), even though the exploration of cutting-edge technology is critical to a firm’s sustained profits and even existence (Roberts, 1999).”
BackgroundMaclagan, L. C., Visanji, N. P., Cheng, Y., Tadrous, M., Lacoste, A. M. B., Kalia, L. V., Bronskill, S. E., & Marras, C. (2020) · Pharmacoepidemiology and Drug Safety · doi:10.1002/pds.5015 · Cited by 39
“…development efforts seeking a potential disease-modifying therapy for PD. 11 Drug development is a time-consuming, expensive and inefficient process 12-14 and, with a growing list of failed clinical trials, pharmaceutical companies are beginning to abandon research efforts to develop a novel…”
BackgroundWang, J., Chen, J., Studts, J., & Wang, G. (2023) · mAbs · doi:10.1080/19420862.2023.2220149 · Cited by 37
Complementary Approaches to Existing Target Based Drug Discovery for Identifying Novel Drug Targets
Vasaikar, S. V., Bhatia, P., Bhatia, P. G., & Yaiw, K.-C. (2016) · Biomedicines · doi:10.3390/biomedicines4040027 · Cited by 38
“The reasons for this decline were uncertain, but it was suspected that drug discovery approaches and development remains major factor [2,5,6].”
BackgroundEfficient design of clinical trials and epidemiological research: is it possible?
Lauer, M. S., Gordon, D., Wei, G. S., & Pearson, G. D. (2017) · Nature Reviews Cardiology · doi:10.1038/nrcardio.2017.60 · Cited by 40
How to Design AI-Driven Clinical Trials in Nuclear Medicine
Delso, G., Cirillo, D., Kaggie, J. D., Valencia, A., Metser, U., & Veit-Haibach, P. (2021) · Seminars in Nuclear Medicine · doi:10.1053/j.semnuclmed.2020.09.003 · Cited by 36
Alternative strategies in cardiac preclinical research and new clinical trial formats
Kreutzer, F. P., Meinecke, A., Schmidt, K., Fiedler, J., & Thum, T. (2022) · Cardiovascular Research · doi:10.1093/cvr/cvab075 · Cited by 36
“4 In fact, merely approximately 8% of selected drug candidates successfully pass all clinical phases and can eventually be introduced to the market.”
BackgroundAdditive manufacturing in nano drug delivery systems
Rahman, M. H., Liza, N. Y., Hossain, K. R., Kalambhe, D. R., Shyeed, M. A., & Noor, D. H. (2024) · Pharmaceutical Science Advances · doi:10.1016/j.pscia.2024.100036 · Cited by 36
“Since the fi rst controlled-release formulation was approved in the 1950s, although the number of novel drug developments has shown a downward trend, research on novel delivery systems has continued to make progress [31, 32].”
The Convergence of Stem Cell Technologies and Phenotypic Drug Discovery
Friese, A., Ursu, A., Hochheimer, A., Schöler, H. R., Waldmann, H., & Bruder, J. M. (2019) · Cell chemical biology · doi:10.1016/j.chembiol.2019.05.007 · Cited by 37
Innovation in pharmaceutical R&D: mapping the research landscape
Romasanta, A. K. S., van der Sijde, P., & van Muijlwijk‐Koezen, J. E. (2020) · Scientometrics · doi:10.1007/s11192-020-03707-y · Cited by 51
“Various factors were associated with this productivity decline, including the discovery of treatments for so-called low hanging fruits, the increased standard needed for new drugs compared to current drugs in the market, the overinvestment in basic research despite the many biological uncertainties (Pammolli et al. 20…”
BackgroundAssessing the impact of automation in pharmaceutical quality control labs using a digital twin
Coito, T., Martins, M. S. E., Firme, B., Figueiredo, J. M. G., Vieira, S. M., & Sousa, J. M. C. (2021) · Journal of Manufacturing Systems · doi:10.1016/j.jmsy.2021.11.014 · Cited by 36
The pain of pain: Challenges of animal behavior models
Barrett, J. E. (2015) · European Journal of Pharmacology · doi:10.1016/j.ejphar.2014.11.046 · Cited by 41
AI-guided pipeline for protein–protein interaction drug discovery identifies a SARS-CoV-2 inhibitor
Trepte, P., Secker, C., Olivet, J., Blavier, J., Kostova, S., Maseko, S. B., Minia, I., Silva Ramos, E., Cassonnet, P., Golusik, S., et al. (2024) · Molecular Systems Biology · doi:10.1038/s44320-024-00019-8 · Cited by 35
“However, the number of newly approved drugs per billion dollars invested per year has decreased in the last 60 years (Scannell et al, 2012; Ringel et al, 2020), and the currently approved small molecules target less than 700 proteins altogether or ~3% of the human protein-coding genome (Harding et…”
BackgroundZhang, L., Chen, C. Y., Fu, J., Lilley, B. N., Berlinicke, C. A., Hansen, B. S., Ding, D., Wang, G., Wang, T., Shou, D., et al. (2021) · eLife · doi:10.7554/elife.57245 · Cited by 35
“However, many promising leads fail during late-stage animal model testing or clinical trials (Munos, 2009; Sams-Dodd, 2013; Scannell et al., 2012).”
BackgroundArtificial intelligence for neurodegenerative experimental models
Marzi, S. J., Schilder, B. M., Nott, A., Frigerio, C. S., Willaime‐Morawek, S., Bucholc, M., Hanger, D. P., James, C. R., Lewis, P. A., Lourida, I., et al. (2023) · Alzheimer s & Dementia · doi:10.1002/alz.13479 · Cited by 35
AI approaches for the discovery and validation of drug targets
Wenteler, A., Cabrera, C., Wei, W., Neduva, V., & Barnes, M. R. (2024) · Cambridge Prisms Precision Medicine · doi:10.1017/pcm.2024.4 · Cited by 51
How soon will digital endpoints become a cornerstone for future drug development?
Boehme, P., Hansen, A., Roubenoff, R., Scheeren, J., Herrmann, M., Mondritzki, T., Ehlers, J. P., & Truebel, H. (2018) · Drug Discovery Today · doi:10.1016/j.drudis.2018.07.001 · Cited by 36
Lee, J., Kumar, S., Lee, S., Park, S. J., & Kim, M. (2019) · Frontiers in Chemistry · doi:10.3389/fchem.2019.00779 · Cited by 37
“Drug R&D is currently facing a productivity crisis to overcome low productivity as well as high risk/high return in the context of economics (Scannell et al., 2012; Mullard, 2014; Mignani et al., 2016; Bendtsen et al., 2017).”
BackgroundBorn, J., Manica, M., Cadow, J., Markert, G., Mill, N. A., Filipavicius, M., Janakarajan, N., Cardinale, A., Laino, T., & Martínez, M. R. (2021) · Machine Learning Science and Technology · doi:10.1088/2632-2153/abe808 · Cited by 43
“Additionally, it takes around 10 years until a typical compound reaches the market [8].”
BackgroundTrends in Deep Learning for Property-driven Drug Design
Born, J., & Manica, M. (2021) · Current Medicinal Chemistry · doi:10.2174/0929867328666210729115728 · Cited by 44
Mott, B. T., He, R., Chen, X., Fox, J. M., Civin, C. I., Arav‐Boger, R., & Posner, G. H. (2013) · Bioorganic & Medicinal Chemistry · doi:10.1016/j.bmc.2013.04.027 · Cited by 35
Crowdsourcing in pharma: a strategic framework
Bentzien, J., Bharadwaj, R., & Thompson, D. C. (2015) · Drug Discovery Today · doi:10.1016/j.drudis.2015.01.011 · Cited by 36
Metadata
- Authors
- Scannell, J. W., Blanckley, A., Boldon, H., & Warrington, B.
- Corresponding author
- Scannell, Jack W.
- ORCID
- Scannell, Jack W.
- Venue
- Nature Reviews Drug Discovery
- Published
- 2012-03
- Volume
- 11
- Issue
- 3
- Pages
- 191-200
- ISSN
- 1474-1776 (ISSN-L)
- 1474-1784
- OpenAlex
- W2028279608
- Cited by
- 1,981
- References
- 85
- Citations by year
- 2026: 135 · 2025: 123 · 2024: 144 · 2023: 126 · 2022: 141 · 2021: 173 · 2020: 178 · 2019: 144 · 2018: 138 · 2017: 133 · 2016: 155 · 2015: 136 · 2014: 108 · 2013: 103 · 2012: 41
- FWCI
- 47.94
- Type
- journal article
- Language
- en
- Open access
- closed
- Licence
- www.springer.com/tdm (tdm)
- Locations
- Nature Reviews Drug Discovery (publishedVersion)
- PubMed (publishedVersion)
- Topics
- Social Sciences › Economics, Econometrics and Finance › Economics and Econometrics › Pharmaceutical Economics and Policy
- Health Sciences › Medicine › Public Health, Environmental and Occupational Health › Health and Medical Research Impacts
- Health Sciences › Nursing › Issues, ethics and legal aspects › Pharmaceutical industry and healthcare
- Keywords
- new drug approvals, drug approval rates, drug development costs, regulatory policy, drug regulation, basic research
- MeSH terms
- Animals, Drug Industry, Pharmaceutical Preparations, Humans, Research, Drug Delivery Systems, Efficiency, Organizational
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.